美国食品药品监督管理局（FDA）批准的用于治疗传染病的药物分析：抗艾滋病毒/艾滋病药物

An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs.

作者信息

Kinch Michael S, Patridge Eric

机构信息

Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA.

出版信息

Drug Discov Today. 2014 Oct;19(10):1510-3. doi: 10.1016/j.drudis.2014.05.012. Epub 2014 May 28.

DOI:10.1016/j.drudis.2014.05.012

PMID:24880109

Abstract

HIV/AIDS is one of the worst pandemics in history. According to the World Health Organization, 26 million people have died since 1981 - 1.6 million in 2012 alone. The dramatic rise in HIV/AIDS mobilized a swift and impressive coordination among governmental, academic and private sector organizations to identify the virus and develop new treatments. Herein, we assess the arsenal of 28 new molecular entities (NMEs) targeting HIV/AIDS. These data demonstrate that the first approval of zidovudine presaged an expansion of the antiviral repertoire over the following years. Whereas the rate of HIV/AIDS NMEs is rapidly declining, so is the number of organizations developing NMEs. We speculate that decisions to abandon further research reflect, in part, growing costs and time required for development.

摘要

艾滋病毒/艾滋病是历史上最严重的大流行病之一。据世界卫生组织统计，自1981年以来已有2600万人死亡，仅2012年就有160万人死亡。艾滋病毒/艾滋病的急剧增加促使政府、学术和私营部门组织迅速进行了令人瞩目的协调，以识别该病毒并开发新的治疗方法。在此，我们评估了针对艾滋病毒/艾滋病的28种新分子实体（NME）的“武器库”。这些数据表明，齐多夫定的首次获批预示着在接下来的几年里抗病毒药物种类的扩大。虽然艾滋病毒/艾滋病NME的获批率正在迅速下降，但开发NME的组织数量也在减少。我们推测，放弃进一步研究的决定部分反映了开发所需成本和时间的不断增加。